HRP20030988A2 - Coenzyme q and eicosapentaenoic acid (epa) - Google Patents
Coenzyme q and eicosapentaenoic acid (epa) Download PDFInfo
- Publication number
- HRP20030988A2 HRP20030988A2 HR20030988A HRP20030988A HRP20030988A2 HR P20030988 A2 HRP20030988 A2 HR P20030988A2 HR 20030988 A HR20030988 A HR 20030988A HR P20030988 A HRP20030988 A HR P20030988A HR P20030988 A2 HRP20030988 A2 HR P20030988A2
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- epa
- acid
- formulations according
- disorder
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 98
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 98
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 98
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000005515 coenzyme Substances 0.000 title 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 53
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 53
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 46
- 229930195729 fatty acid Natural products 0.000 claims abstract description 46
- 239000000194 fatty acid Substances 0.000 claims abstract description 46
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 46
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 44
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 44
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 32
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 18
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 16
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 16
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 16
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 11
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract description 7
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract description 7
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 7
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 7
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract description 6
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 5
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 208000020016 psychiatric disease Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 125000004494 ethyl ester group Chemical class 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000004118 muscle contraction Effects 0.000 claims description 6
- 210000004994 reproductive system Anatomy 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 208000026723 Urinary tract disease Diseases 0.000 claims description 5
- 208000012931 Urologic disease Diseases 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 229960004274 stearic acid Drugs 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 208000014001 urinary system disease Diseases 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010005052 Bladder irritation Diseases 0.000 claims description 4
- 206010007027 Calculus urinary Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 102000006311 Cyclin D1 Human genes 0.000 claims description 4
- 108010058546 Cyclin D1 Proteins 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000007101 Muscle Cramp Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 208000005392 Spasm Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000030963 borderline personality disease Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000027758 ovulation cycle Effects 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 208000008281 urolithiasis Diseases 0.000 claims description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- 206010006298 Breast pain Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000006662 Mastodynia Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 229940079920 digestives acid preparations Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000006011 Stroke Diseases 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 208000009911 Urinary Calculi Diseases 0.000 claims 2
- 208000022458 calcium metabolism disease Diseases 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 208000015202 calcium metabolic disease Diseases 0.000 claims 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 description 11
- 235000004626 essential fatty acids Nutrition 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 6
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960002600 icosapent ethyl Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 101710153103 Long-chain-fatty-acid-CoA ligase FadD13 Proteins 0.000 description 1
- 101710153099 Long-chain-fatty-acid-CoA ligase FadD15 Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 101710154693 Medium/long-chain-fatty-acid-CoA ligase FadD17 Proteins 0.000 description 1
- 101710141422 Medium/long-chain-fatty-acid-CoA/3-oxocholest-4-en-26-oate-CoA ligase Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 102000006447 Phospholipases A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229920001550 polyprenyl Polymers 0.000 description 1
- 125000001185 polyprenyl group Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113104A GB0113104D0 (en) | 2001-05-30 | 2001-05-30 | Coenzyme Q and EPA |
| GB0123446A GB0123446D0 (en) | 2001-09-28 | 2001-09-28 | Coenzyme Q and EPA |
| PCT/GB2002/002148 WO2002096408A1 (fr) | 2001-05-30 | 2002-05-09 | Coenzyme q et acide eicosapentaenoique (epa) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030988A2 true HRP20030988A2 (en) | 2004-06-30 |
Family
ID=26246133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030988A HRP20030988A2 (en) | 2001-05-30 | 2003-11-27 | Coenzyme q and eicosapentaenoic acid (epa) |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20020198177A1 (fr) |
| EP (1) | EP1390025B1 (fr) |
| JP (1) | JP2004531568A (fr) |
| KR (1) | KR20040004652A (fr) |
| CN (1) | CN1268328C (fr) |
| AT (1) | ATE291910T1 (fr) |
| BR (1) | BR0209749A (fr) |
| CA (1) | CA2449199A1 (fr) |
| CZ (1) | CZ299784B6 (fr) |
| DE (1) | DE60203494T2 (fr) |
| EE (1) | EE200300599A (fr) |
| ES (1) | ES2238568T3 (fr) |
| HK (1) | HK1058883A1 (fr) |
| HR (1) | HRP20030988A2 (fr) |
| HU (1) | HUP0401343A3 (fr) |
| IL (2) | IL159038A0 (fr) |
| IS (1) | IS7005A (fr) |
| MX (1) | MXPA03010888A (fr) |
| NO (1) | NO20035281L (fr) |
| NZ (1) | NZ529339A (fr) |
| PL (1) | PL364093A1 (fr) |
| PT (1) | PT1390025E (fr) |
| RU (1) | RU2003133142A (fr) |
| SK (1) | SK14502003A3 (fr) |
| WO (1) | WO2002096408A1 (fr) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| JP4859314B2 (ja) * | 2001-09-26 | 2012-01-25 | 株式会社カネカ | 潰瘍性大腸炎および／又はクローン病治療剤 |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| CN100536828C (zh) | 2002-11-04 | 2009-09-09 | 加拿大海洋营养保健品有限公司 | 具有多重壳的微胶囊及其制备方法 |
| CN1294825C (zh) * | 2003-03-25 | 2007-01-17 | 汕头市金园区丹味食品发展中心 | 一种营养粉及其制备方法 |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| GB2422373B (en) | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| US20070082949A1 (en) * | 2003-11-14 | 2007-04-12 | Hiroaki Ootani | Agent for preventing and treating language disorders |
| AU2005208832A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
| CN110522717A (zh) | 2004-01-22 | 2019-12-03 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
| ZA200607794B (en) * | 2004-04-16 | 2008-05-28 | Solvay Pharm Gmbh | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
| ES2247939B1 (es) * | 2004-08-19 | 2007-04-01 | Fernando Jose Garcia Fructuoso | Suplemento alimenticio basado en la utilizacion de acidos grasos omega-3 (dha-epa) para el tratamiento del sindrome de fatiga cronica. |
| CN1319534C (zh) * | 2004-10-28 | 2007-06-06 | 昆明翔昊科技有限公司 | 含番茄红素和辅酶q10的制剂及其制备方法 |
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| ATE452120T1 (de) | 2005-01-27 | 2010-01-15 | Ocean Nutrition Canada Ltd | Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| US9968120B2 (en) | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
| US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
| GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
| ES2836184T3 (es) * | 2006-05-02 | 2021-06-24 | Univ Miami | Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas |
| EP2040682B1 (fr) | 2006-06-05 | 2017-07-26 | DSM Nutritional Products AG | Microcapsules à enveloppes améliorées |
| NZ578872A (en) | 2007-01-10 | 2012-07-27 | Ocean Nutrition Canada Ltd | Vegetarian microcapsules |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| AU2008239318B2 (en) * | 2007-03-15 | 2013-10-03 | Suntory Holdings Limited | Anti-fatigue agent |
| WO2008113177A1 (fr) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprenant des monoglycérides d'acides gras polyinsaturés ou des dérivés de ceux-ci et leurs utilisations |
| DE102007055344A1 (de) | 2007-11-19 | 2009-05-20 | K. D. Pharma Bexbach Gmbh | Neue Verwendung von Omega-3-Fettsäure(n) |
| ITMI20080145A1 (it) * | 2008-01-30 | 2009-07-31 | Pharmanutra S R L | Uso di acido eicosapentanoico e/o docosaesanoico in donne con endometriosi |
| US20090197955A1 (en) * | 2008-01-31 | 2009-08-06 | Monsanto Company | Methods of improving dha deposition and related function and/or development |
| US20110136231A1 (en) | 2008-04-11 | 2011-06-09 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
| PL2334295T3 (pl) | 2008-09-02 | 2017-12-29 | Amarin Pharmaceuticals Ltd | Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania |
| SI3037089T1 (sl) | 2009-02-10 | 2020-03-31 | Amarin Pharmaceuticals Ireland Limited, | Etilester eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
| EP3797591A1 (fr) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique stable et procédés d'utilisation associés |
| BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CN102483419B (zh) | 2009-05-11 | 2017-12-15 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断代谢障碍的方法 |
| KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
| KR101106166B1 (ko) * | 2009-06-25 | 2012-01-20 | (주)카이센 | 터널 라이닝 내공변위 측정 장치 |
| SG10201405994UA (en) * | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| JP5934102B2 (ja) * | 2009-10-30 | 2016-06-15 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ誘導体による酸化ストレス障害の緩和 |
| MX337315B (es) * | 2010-03-04 | 2016-02-25 | Amarin Pharma Inc | Composiciones y metodos para tratar y/o prevenir enfermedad cardiovascular. |
| US8178707B2 (en) | 2010-03-25 | 2012-05-15 | Jost Chemical Company | Co-precipitated salts of fatty acids |
| DE102010050570A1 (de) * | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| CN102533799A (zh) * | 2010-12-24 | 2012-07-04 | 上海市农业科学院 | 一种源于阴沟肠杆菌的泛醌辅酶q10合成酶基因及其制备方法 |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| RU2458687C1 (ru) * | 2011-03-21 | 2012-08-20 | Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) | Способ коррекции липопероксидации при гиполипидемической терапии пациентов с метаболическим синдромом |
| US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
| AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
| KR102014526B1 (ko) | 2011-04-26 | 2019-08-26 | 레트로토프 인코포레이티드 | Ｐｕｆａ 산화와 관련된 장애 |
| EP2701695B1 (fr) | 2011-04-26 | 2019-04-03 | Retrotope, Inc. | Maladies neurodégénératives et maladies musculaires impliquant des acides gras polyinsaturés |
| JP6106158B2 (ja) | 2011-04-26 | 2017-03-29 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | 酸化的網膜疾患 |
| EP3730135A1 (fr) | 2011-04-26 | 2020-10-28 | Retrotope, Inc. | Troubles de traitement compromis de l'énergie et déficiences mitochondriales |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (fr) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Méthodes de traitement de l'hypertriglycéridémie |
| WO2013071281A1 (fr) * | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters de dcpla et méthodes de traitement les utilisant |
| ES2417679B1 (es) * | 2011-12-09 | 2014-09-15 | Servicio Andaluz De Salud | Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria. |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| HUE053111T2 (hu) | 2012-06-29 | 2021-06-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával |
| US8673325B1 (en) * | 2012-09-06 | 2014-03-18 | Dignity Sciences Limited | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
| WO2014074552A2 (fr) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine |
| US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| AU2014251045B2 (en) | 2013-04-08 | 2019-06-13 | Berg Llc | Treatment of cancer using coenzyme Q10 combination therapies |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150051282A1 (en) * | 2013-08-14 | 2015-02-19 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy |
| NZ717504A (en) | 2013-09-04 | 2022-07-01 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US9138453B2 (en) | 2013-10-14 | 2015-09-22 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
| EP3151825B1 (fr) | 2014-06-04 | 2020-03-25 | DS Biopharma Limited | Compositions pharmaceutiques contenant du dgla et utilisations de celles-ci |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (fr) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires |
| RU2554806C1 (ru) * | 2014-07-29 | 2015-06-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа |
| WO2016181221A1 (fr) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprenant du 15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| US20170020836A1 (en) | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| EP3950649A1 (fr) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Marquage isotopique spécifique de site de systèmes 1,4-diènes |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| JP2020503388A (ja) * | 2016-12-23 | 2020-01-30 | ビーエーエスエフ エーエス | 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物 |
| CA3063916A1 (fr) | 2017-05-17 | 2018-11-22 | Berg Llc | Utilisation de formulations de coenzyme q10 dans le traitement et la prevention de l'epidermolyse bulleuse |
| WO2018213663A1 (fr) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite |
| JP7236382B2 (ja) * | 2017-06-12 | 2023-03-09 | 昇平 宮田 | 抗癌剤及びその使用 |
| WO2019153073A1 (fr) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Monoglycérides d'acides gras polyinsaturés, compositions, procédés et utilisations correspondants |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CA3054203C (fr) | 2018-05-03 | 2021-01-05 | Scf Pharma Inc. | Monoglycerides d'acides gras polyinsatures, compositions, procedes et utilisations de ceux-ci |
| PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
| EP4107163A4 (fr) | 2020-02-21 | 2024-06-19 | Retrotope, Inc. | Procédés de modification isotopique d'acides gras polyinsaturés et leurs dérivés |
| JP2023533192A (ja) * | 2020-07-09 | 2023-08-02 | ディーエスエム アイピー アセッツ ビー．ブイ． | 腸内細菌叢におけるディアリスター属菌（Ｄｉａｌｉｓｔｅｒ ｓｐｐ．）の菌数を増加させる方法 |
| US11491130B2 (en) * | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
| US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
| WO2022225896A1 (fr) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction du risque d'insuffisance cardiaque |
| WO2023023397A1 (fr) * | 2021-08-20 | 2023-02-23 | Retrotope, Inc | Méthodes d'inhibition de la progression de maladies neurodégénératives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
| CA2052577C (fr) * | 1991-10-01 | 2000-01-11 | Michael John Tisdale | Usages therapeutiques de l'acide eicosapentanoique |
| GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
-
2002
- 2002-05-09 PL PL02364093A patent/PL364093A1/xx not_active Application Discontinuation
- 2002-05-09 JP JP2002592918A patent/JP2004531568A/ja active Pending
- 2002-05-09 HU HU0401343A patent/HUP0401343A3/hu unknown
- 2002-05-09 KR KR10-2003-7015381A patent/KR20040004652A/ko not_active Application Discontinuation
- 2002-05-09 BR BR0209749-4A patent/BR0209749A/pt not_active IP Right Cessation
- 2002-05-09 IL IL15903802A patent/IL159038A0/xx active IP Right Grant
- 2002-05-09 CZ CZ20033196A patent/CZ299784B6/cs not_active IP Right Cessation
- 2002-05-09 EP EP02724475A patent/EP1390025B1/fr not_active Expired - Lifetime
- 2002-05-09 PT PT02724475T patent/PT1390025E/pt unknown
- 2002-05-09 DE DE60203494T patent/DE60203494T2/de not_active Expired - Fee Related
- 2002-05-09 EE EEP200300599A patent/EE200300599A/xx unknown
- 2002-05-09 US US10/140,867 patent/US20020198177A1/en not_active Abandoned
- 2002-05-09 NZ NZ529339A patent/NZ529339A/en unknown
- 2002-05-09 CA CA002449199A patent/CA2449199A1/fr not_active Abandoned
- 2002-05-09 SK SK14502003A patent/SK14502003A3/sk not_active Application Discontinuation
- 2002-05-09 RU RU2003133142/15A patent/RU2003133142A/ru not_active Application Discontinuation
- 2002-05-09 AT AT02724475T patent/ATE291910T1/de not_active IP Right Cessation
- 2002-05-09 WO PCT/GB2002/002148 patent/WO2002096408A1/fr active IP Right Grant
- 2002-05-09 MX MXPA03010888A patent/MXPA03010888A/es unknown
- 2002-05-09 ES ES02724475T patent/ES2238568T3/es not_active Expired - Lifetime
- 2002-05-09 CN CNB028110110A patent/CN1268328C/zh not_active Expired - Fee Related
-
2003
- 2003-10-30 IS IS7005A patent/IS7005A/is unknown
- 2003-11-24 IL IL159038A patent/IL159038A/en not_active IP Right Cessation
- 2003-11-27 NO NO20035281A patent/NO20035281L/no not_active Application Discontinuation
- 2003-11-27 HR HR20030988A patent/HRP20030988A2/hr not_active Application Discontinuation
-
2004
- 2004-03-11 HK HK04101780A patent/HK1058883A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401343A2 (hu) | 2004-11-29 |
| ATE291910T1 (de) | 2005-04-15 |
| IL159038A0 (en) | 2004-05-12 |
| BR0209749A (pt) | 2004-07-27 |
| EE200300599A (et) | 2004-02-16 |
| WO2002096408A1 (fr) | 2002-12-05 |
| CA2449199A1 (fr) | 2002-12-05 |
| EP1390025B1 (fr) | 2005-03-30 |
| CN1268328C (zh) | 2006-08-09 |
| DE60203494T2 (de) | 2006-02-09 |
| IS7005A (is) | 2003-10-30 |
| US20020198177A1 (en) | 2002-12-26 |
| RU2003133142A (ru) | 2005-04-20 |
| MXPA03010888A (es) | 2004-02-27 |
| SK14502003A3 (en) | 2004-10-05 |
| EP1390025A1 (fr) | 2004-02-25 |
| PT1390025E (pt) | 2005-08-31 |
| DE60203494D1 (de) | 2005-05-04 |
| JP2004531568A (ja) | 2004-10-14 |
| KR20040004652A (ko) | 2004-01-13 |
| NZ529339A (en) | 2004-08-27 |
| NO20035281D0 (no) | 2003-11-27 |
| NO20035281L (no) | 2003-11-27 |
| CN1522143A (zh) | 2004-08-18 |
| CZ20033196A3 (cs) | 2004-06-16 |
| IL159038A (en) | 2007-07-04 |
| ES2238568T3 (es) | 2005-09-01 |
| CZ299784B6 (cs) | 2008-11-26 |
| PL364093A1 (en) | 2004-12-13 |
| HK1058883A1 (en) | 2004-06-11 |
| HUP0401343A3 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20030988A2 (en) | Coenzyme q and eicosapentaenoic acid (epa) | |
| AU2002255164B2 (en) | Potentiation of therapeutic effects of fatty acids | |
| US4407821A (en) | Lipidic compositions for use in dietetics, reanimation and therapeutics | |
| RU2276975C2 (ru) | Терапевтические комбинации жирных кислот | |
| TW323230B (fr) | ||
| US5436269A (en) | Method for treating hepatitis | |
| AU2002255164A1 (en) | Potentiation of therapeutic effects of fatty acids | |
| AU2001274276A1 (en) | Therapeutic combinations of fatty acids | |
| JPH02104522A (ja) | 脂肪酸を含有する医薬用組成物 | |
| WO2012049222A2 (fr) | Nouvelles compositions contenant des acides gras oméga-3 et oméga-6 et leurs utilisations | |
| CA2631343A1 (fr) | La combination d'acides omega-3 et d'hormone thyroide pour le traitement de la maladie d'alzheimer | |
| WO1998048788A1 (fr) | Traitement de la depression et de l'anxiete au moyen d'acide docosahexaenoique ou d'antioxydants naturels | |
| CN106031722A (zh) | 治疗身体和神经系统失调或炎症引起的疾病的组合物及应用 | |
| AU2002255167B2 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
| JP2005247853A (ja) | 食欲または食物摂取を抑制するための不飽和脂肪酸の使用 | |
| AU2002255167A1 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
| US20200085774A1 (en) | Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia | |
| Marak et al. | Fish Oils in Health and Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040517 Year of fee payment: 3 |
|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBI | Application refused |